Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. - Wikidata - awgldk - TriplyDB

Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40.

Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40.

http://www.wikidata.org/entity/Q35790354

about

Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilization CD134 as target for specific drug delivery to auto-aggressive CD4+ T cells in adjuvant arthritis CD8 T Cell-Independent Antitumor Response and Its Potential for Treatment of Malignant Gliomas The Promise of Preventive Cancer Vaccines Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications The role of costimulatory receptors of the tumour necrosis factor receptor family in atherosclerosis Immunotherapy in the treatment of non-small cell lung cancer Treg functional stability and its responsiveness to the microenvironment Science gone translational: the OX40 agonist story OX40 ligand plays an important role in the development of atherosclerosis through vasa vasorum neovascularization Involvement of HAb18G/CD147 in T cell activation and immunological synapse formation.The adaptor TRAF5 limits the differentiation of inflammatory CD4(+) T cells by antagonizing signaling via the receptor for IL-6.Indispensable roles of OX40L-derived signal and epistatic genetic effect in immune-mediated pathogenesis of spontaneous pulmonary hypertension.Costimulatory pathways in transplantation.Activation of OX40 augments Th17 cytokine expression and antigen-specific uveitis.OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity.OX40L blockade and allergen-induced airway responses in subjects with mild asthma CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma.Small-molecule modulators of the OX40-OX40 ligand co-stimulatory protein-protein interaction Simvastatin reduces OX40 and OX40 ligand expression in human peripheral blood mononuclear cells and in patients with atherosclerotic cerebral infarction.OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy.Classification of current anticancer immunotherapies Cell surface signaling molecules in the control of immune responses: a tide model.Role of co-stimulation in Leishmaniasis Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma.Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1.New insights on OX40 in the control of T cell immunity and immune tolerance in vivo K562-Derived Whole-Cell Vaccine Enhances Antitumor Responses of CAR-Redirected Virus-Specific Cytotoxic T Lymphocytes In Vivo.CD40 ligand enhances immunogenicity of vector-based vaccines in immunocompetent and CD4+ T cell deficient individuals.Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain Regulation of the PKCθ-NF-κB Axis in T Lymphocytes by the Tumor Necrosis Factor Receptor Family Member OX40 OX40 costimulation turns off Foxp3+ Tregs.OX40 ligand expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity in mice.Immunotherapy for pancreatic cancer - science driving clinical progress.Genetic and genomic insights into the molecular basis of atherosclerosis.In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right CD40/CD40L expression correlates with the survival of patients with glioblastomas and an augmentation in CD40 signaling enhances the efficacy of vaccinations against glioma models.Towards a therapeutic breast cancer vaccine: the next steps.

P2860

Q24318411-8549969F-2DA5-4929-9A7A-BB4E8D324469 Q24816831-C15AC865-0677-48A4-A520-CBDD161368F2 Q26740520-7F32AAB3-D445-40A4-8BDF-9B2A9919B45C Q26783742-BBC78C9B-4DFA-4555-8A10-CB898DE8FAC9 Q26996518-88D2A4E0-D7F5-4A04-B3D2-F580CE9BDCF6 Q26996707-28ECA6BE-F7F2-494B-B91D-34D0A534CB4B Q27000382-E334653E-954F-4F0D-A452-DB2AC2C4426A Q27008946-B79AF21F-AA6A-4604-ACAD-D5916EB4D059 Q27022436-2C55BB74-0EA5-4DC2-8322-3AE4D8650FCE Q28506359-C1EC1B91-128B-4271-BCB8-D9C7255A5236 Q33524885-A2B14FB6-B9E2-4ED0-82CB-6FA2B0D7AE71 Q33940420-B2D5269F-1577-43A7-B512-2A7C34E5A13F Q34101823-FC41C23F-A1FB-4E9A-AF2C-31557189F6A2 Q34187594-079B4B31-C5F5-465F-8919-B54DD70EBEA9 Q34358363-361A52A7-EA24-4890-9150-E001F1EEE1AE Q34477650-58996EAA-BFA3-45B8-9839-86651B53419D Q34620982-4E837A2C-F5C5-47BA-859C-AE8D1B66D3AF Q34692141-6C0E613B-D2B2-402E-ABD5-4249BF01719A Q34707183-3A2559A2-141B-42C6-8D5F-CB4406988AB3 Q34954124-F6D4ABAB-774D-4E4A-8A9E-3D9AC9900726 Q34991508-863A1745-F6AF-48DC-AD25-A384DB53AC69 Q35118177-FEF60C8F-B678-4BF3-AF74-60A7CC44F179 Q35149637-4198A7D9-D5C7-44C8-9CDA-265CF743A0FB Q35223235-9660A243-22B1-4E5C-B288-1B4B77A05D88 Q35566850-35350E2A-05D3-4337-866D-FB083CE82470 Q35651705-4826699F-D89D-4005-B7CF-84A7B6FD5AFD Q35676793-740A0A0B-4CBC-4383-94A7-20402D8BABA5 Q35685810-CC39CA43-788A-476D-85AF-53F504AFFE22 Q35812085-D838BEA8-018E-478C-B77E-1494C7E138DF Q35854792-7510AC48-39EE-47EF-B9C5-D80183256D5D Q35946627-A19C3206-64D2-412D-BCC2-F05E5B10862C Q35990308-D9EA4E09-14DF-4727-A2CE-45619F2C0726 Q36007580-2E4BD78B-2F07-4F35-A1EF-8C33AC851F98 Q36099421-92A67006-B976-4CDF-9EA8-8D3E5884D22E Q36133140-DCB82682-0733-457C-8FFF-A4724548E578 Q36155114-F84EAEED-32E0-41F8-A62A-B2E34FBB8374 Q36173559-A56DC7DB-B74C-47C1-ADD1-AB26918DF3B7 Q36224132-352C90EE-BFAD-4C5C-ADBF-D52742975F14 Q36288270-A718F273-8CDA-43F7-A9E5-83BFCCE4BE88 Q36350565-059B4089-4CD9-439A-BF55-885DFD3DF3AA

P2860

Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40.

http://www.wikidata.org/entity/Q35790354

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40.

@ast

Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40.

@en

type

label

Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40.

@ast

Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40.

@en

prefLabel

Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40.

@ast

Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40.

@en

P1433

Q35790354-DA7612A1-7841-4228-9F01-207415CBC1A6

P1476

Q35790354-DF0F96B9-B53F-43A6-943A-3E6DB2A1B921

P2093

Q35790354-4E88ECD8-445D-49AC-9FA0-FCCC11AA2BFE

Q35790354-A23147DC-9923-4FF4-91D5-44F16AAD56BC

Q35790354-B50C39F7-8913-428E-B92D-04F19B886516

P2860

Q35790354-000162D3-0254-4EE0-9CB6-B473D299AC95

Q35790354-0074FFD6-1F33-46D9-BBC0-A08286CA48B8

Q35790354-03AC7242-2C86-4E7D-9F97-97BB36506A0F

Q35790354-11A81936-2859-48A1-9E67-AE3A5392B97D

Q35790354-18D2B98F-0DC7-4782-B8D1-78094C7924DD

Q35790354-19F43866-6C0E-4383-8B10-F646E3C94C06

Q35790354-20EC6882-9C7C-4E5F-A04C-C53F86C34043

Q35790354-2D272C3D-A33B-4333-99A4-F3C344ACF06D

Q35790354-3032EE10-A881-4295-A733-0D55EDF6E979

Q35790354-3111923F-5AF6-467F-AE0C-C05ED78C3ABE

P304

Q35790354-D4757FA9-3DB5-4BC2-BED8-F501EA2AF57E

P31

Q35790354-688B716D-A126-44C2-9947-96886956013B

P356

Q35790354-3E696F03-9E45-47A1-A23A-A435F40F4BBD

P433

Q35790354-0636A5EE-9E4B-41F9-8217-A9E7CE43ACFC

P478

Q35790354-A796CDE9-C387-4149-849E-2708FC324D24

P577

Q35790354-AE10BAB5-F9D6-46D5-B59A-F1A71E71F26D

P698

Q35790354-C699D742-FE81-422C-8436-E56BA0EB1AC9

P356

P1433

Nature Reviews Immunology

P1476

Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40.

@en

P2093

Andrew D Weinberg

http://www.w3.org/2001/XMLSchema#string

Kazuo Sugamura

http://www.w3.org/2001/XMLSchema#string

Naoto Ishii

http://www.w3.org/2001/XMLSchema#string

P2860

CD28/B7 system of T cell costimulation

Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells

A critical role for OX40 in T cell-mediated immunopathology during lung viral infection

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells

Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?

The costimulation-regulated duration of PKB activation controls T cell longevity

OX40/OX40L interaction induces the expression of CXCR5 and contributes to chronic colitis induced by dextran sulfate sodium in mice

The role of OX40 ligand interactions in the development of the Th2 response to the gastrointestinal nematode parasite Heligmosomoides polygyrus

Costimulatory molecule OX40L is critical for both Th1 and Th2 responses in allergic inflammation

P304

420-431

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRI1371

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2004-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15173831

http://www.w3.org/2001/XMLSchema#string